Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Promising trial for Chiron’s avian flu treatment
The H9N2 influenza strain has infected a small number of people and may have the potential to cause a human pandemic. The 96-patient study explored the safety and
The H9N2 influenza strain has infected a small number of people and may have the potential to cause a human pandemic. The 96-patient study explored the safety and
The approval is based on a pivotal phase III double-blind study that compared Kepivance with placebo in the development of oral mucositis in patients with hematologic malignancies. In
Under the agreement with the Department of Health and Human Services (HHS), Chiron will provide a bulk stockpile of H5N1 influenza vaccine, which the company will produce at
Researchers at Monash University and the Sloan Kettering Cancer Center in New York, have uncovered the structure of the molecular switch that controls communication between tumor cells. The
Biolex will use its Lex System for protein expression to create a commercial line for Kringle’s NK4 protein, currently in preclinical development for the treatment of multiple cancers.
The study demonstrated strong clinical and statistical significance that PreHistin, when administered before and during allergy season, clearly and noticeably resulted in fewer allergy symptoms compared with placebo.
Under the terms of the agreement, pSivida will manufacture BrachySil and Beijing Med-Pharm will be responsible for clinical development, securing regulatory approval, marketing and distribution in China. pSivida
The multi-center phase I/II clinical study will evaluate Avrina, Corgentech’s NF-kappaB decoy drug candidate for the treatment of atopic dermatitis (eczema). This is the first of two planned
This trial is in addition to two other recently-announced non-US trials of the product, in ischemia applications, that have received regulatory clearance to proceed. The UK Medicines and
As a result of stroke the patient, Ian McBride, lost the use of his left arm and leg through paralysis. Although he had undergone traditional treatment for stroke